Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butylphthalide plus ticagrelor for atherosclerotic transient ischemic attack or minor stroke
ChiCTR2100042290Phase 4Recruiting
- Sponsor
- Heze Municipal Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of butylphthalide and ticagrelor in transient ischaemic attack (TIA) and ischemic stroke (2 arms), sponsored by Heze Municipal Hospital. Primary endpoint: Composite event of stroke, transient ischemic attack, acute coronary syndrome, or death. Started Jan 2021; status: recruiting.
02
Drugs
butylphthalideticagrelor
03
Conditions
transient ischaemic attack (TIA)ischemic stroke
Beyond the preview
Go deeper on ChiCTR2100042290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042290.